Fig. 6
From: A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Predictive docking patterns of BM38 CAR to MM cells. a Hypothetical structure of the anti-BCMA scFv and anti-CD38 scFv joined with an (EAAAK)3 linker (not shown). b Most favorable docking models of the anti-BCMA scFv with 51 amino acid residues of the extracellular domain of BCMA (2kn1.pdb); c Most favorable docking models of the anti-CD38 scFv with 257 amino acid residues of the extracellular domain of CD38 (1yh3.pdb); d Dual docking of BM38 CAR with BCMA and CD38. e Theoretical single combination pattern of the anti-CD38 scFv and CD38 on MM cells. f Theoretical single combination pattern of the anti-BCMA scFv and BCMA on MM cells. g Theoretical double-binding pattern of the bispecific BM38 CAR to BCMA and CD38 on MM cells. h–i The CD38 extracellular domain contains 257 amino acids and the BCMA extracellular chain consists of only 54 amino acids. The anti-BCMA scFv and anti-CD38 scFv contain 246 and 249 amino acids, respectively. Theoretically, CD38 binding might assist the anti-BCMA scFv in binding to BCMA on myeloma cells, and BCMA coalescence would reversely strengthen CD38 binding